PATHOGENESIS OF INTESTINAL DYSFUNCTION IN SIMIAN AIDS

猿猴艾滋病肠功能障碍的发病机制

基本信息

  • 批准号:
    8357341
  • 负责人:
  • 金额:
    $ 9.57万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-05-01 至 2012-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The efficacy of antiretroviral therapy (ART) in HIV-1 infected individuals is determined by restoration of peripheral blood CD4+ T cell numbers and viral suppression. However, peripheral blood represents only 2% of the total lymphocytes in the body. In contrast, gut associated lymphoid tissue (GALT) harbors 80% of the lymphocytes in the body. Our previous studies showed that severe CD4+ T cell depletion occurs in GALT during primary HIV infection and that CD4+ T cell restoration in GALT is modest and slow compared to peripheral blood during ART. These changes in GALT are not adequately reflected in peripheral blood analysis. The kinetics and mechanisms of CD4+ T cell restoration and function in GALT following ART have not been fully determined. Simian immunodeficiency virus (SIV) infected rhesus macaques provide an excellent animal model to study the gut mucosal immune system in comparison to peripheral blood compartment. The overall objective of this research proposal is to examine the suppression of viral replication and kinetics and mechanisms of restoration of gut mucosal immune system and function in comparison to mucosal and peripheral lymph nodes and peripheral blood in rhesus macaques starting ART (combination of PMPA and FTC) during primary or chronic SIV infection. Our hypothesis is that slow restoration of CD4+ T cells in GALT during therapy can be attributed to the disruption of the functional organization of the gut mucosal tissue occurring very early in SIV infection and this may not adequately support survival and maintenance of the CD4+ T cells homing to gut mucosa. Longitudinal evaluation in the SIV model will lead to characterization of the mechanisms and relationship between CD4+ T cell restoration in GALT, peripheral blood, and lymph node compartments (peripheral, and those draining mucosal sites). There are 3 specific aims. In rhesus macaques initiating ART during primary or chronic SIV infection, (1) to determine suppression of SIV replication and genomic diversity, and the kinetics of CD4+ T cell restoration in GALT in comparison to peripheral blood and lymph nodes; (2) to determine the homing and survival of CD4+ T cells in the GALT microenvironment and (3) to investigate the molecular processes involved in the restoration of gut mucosal immune system. The proposal capitalizes on our experience in enteropathogenic studies in the SIV model, expertise in multi-color flow cytometry, in vivo molecular imaging, autologous T cell transfer and gene expression methodologies. The proposed studies promise to provide valuable insights into the impact of impaired gut microenvironment on the viral suppression and restoration of gut mucosal immune system compared to mucosal and peripheral lymph node compartments, and molecular basis of pathophysiologic processes in GALT.
这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的, 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量, 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 抗逆转录病毒疗法(ART)在HIV-1感染者中的疗效取决于外周血CD 4 + T细胞数量的恢复和病毒抑制。然而,外周血仅占体内淋巴细胞总数的2%。相比之下,肠道相关淋巴组织(GALT)拥有体内80%的淋巴细胞。我们以前的研究表明,严重的CD 4 + T细胞耗竭发生在GALT在原发性HIV感染和GALT中的CD 4 + T细胞的恢复是温和和缓慢的外周血相比,在ART。GALT的这些变化没有充分反映在外周血分析。ART后GALT中CD 4 + T细胞恢复和功能的动力学和机制尚未完全确定。猴免疫缺陷病毒(SIV)感染的恒河猴为研究肠道粘膜免疫系统提供了一个很好的动物模型。本研究提案的总体目标是检查在原发性或慢性SIV感染期间开始ART(PMPA和FTC组合)的恒河猴中,与粘膜和外周淋巴结和外周血相比,对病毒复制的抑制以及肠道粘膜免疫系统和功能恢复的动力学和机制。我们的假设是,治疗期间GALT中CD 4 + T细胞的缓慢恢复可归因于SIV感染早期发生的肠粘膜组织功能组织的破坏,这可能不足以支持归巢至肠粘膜的CD 4 + T细胞的存活和维持。SIV模型中的纵向评价将导致GALT、外周血和淋巴结隔室(外周和引流粘膜部位)中CD 4 + T细胞恢复之间的机制和关系的表征。有三个具体目标。在原发或慢性SIV感染期间启动ART的恒河猴中,(1)确定与外周血和淋巴结相比,GALT中SIV复制和基因组多样性的抑制,以及CD 4 + T细胞恢复的动力学;(2)确定CD 4 + T细胞在GALT微环境中的归巢和存活,以及(3)探讨肠道黏膜免疫系统恢复的分子机制。该提案利用了我们在SIV模型肠道致病性研究方面的经验,多色流式细胞术,体内分子成像,自体T细胞转移和基因表达方法学方面的专业知识。拟议的研究有望提供有价值的见解受损的肠道微环境对病毒的抑制和肠道粘膜免疫系统的恢复相比,粘膜和外周淋巴结隔室,和GALT的病理生理过程的分子基础的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Satya Dandekar其他文献

Satya Dandekar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Satya Dandekar', 18)}}的其他基金

Molecules and Pathways at the Coccidioides Host-Pathogen Interface
球孢子菌宿主-病原体界面的分子和途径
  • 批准号:
    10364963
  • 财政年份:
    2022
  • 资助金额:
    $ 9.57万
  • 项目类别:
Immune and metabolic correlates of Coccidioides disease spectrum and outcomes
球孢子菌疾病谱和结果的免疫和代谢相关性
  • 批准号:
    10540815
  • 财政年份:
    2022
  • 资助金额:
    $ 9.57万
  • 项目类别:
Molecules and Pathways at the Coccidioides Host-Pathogen Interface
球孢子菌宿主-病原体界面的分子和途径
  • 批准号:
    10540795
  • 财政年份:
    2022
  • 资助金额:
    $ 9.57万
  • 项目类别:
Immune and metabolic correlates of Coccidioides disease spectrum and outcomes
球孢子菌疾病谱和结果的免疫和代谢相关性
  • 批准号:
    10364969
  • 财政年份:
    2022
  • 资助金额:
    $ 9.57万
  • 项目类别:
"Corral and Kill" strategy for HIV eradication using MSC in an SIV model
在 SIV 模型中使用 MSC 根除 HIV 的“围堵和杀死”策略
  • 批准号:
    10023879
  • 财政年份:
    2020
  • 资助金额:
    $ 9.57万
  • 项目类别:
"Corral and Kill" strategy for HIV eradication using MSC in an SIV model
在 SIV 模型中使用 MSC 根除 HIV 的“围堵和杀死”策略
  • 批准号:
    10368941
  • 财政年份:
    2020
  • 资助金额:
    $ 9.57万
  • 项目类别:
"Corral and Kill" strategy for HIV eradication using MSC in an SIV model
在 SIV 模型中使用 MSC 根除 HIV 的“围堵和杀死”策略
  • 批准号:
    10579905
  • 财政年份:
    2020
  • 资助金额:
    $ 9.57万
  • 项目类别:
Early HIV Effects on Gut Immunity and Inflammation for Seeding Viral Reservoirs
早期艾滋病毒对肠道免疫和炎症的影响,以播种病毒库
  • 批准号:
    9154447
  • 财政年份:
    2016
  • 资助金额:
    $ 9.57万
  • 项目类别:
33rd Annual Symposium on NHP Models for AIDS
第 33 届 NHP 艾滋病模型年度研讨会
  • 批准号:
    9065384
  • 财政年份:
    2015
  • 资助金额:
    $ 9.57万
  • 项目类别:
INTESTINAL CYTOKINE AND T CELL HEMEOSTASIS IN SIV INFECTION
SIV 感染中的肠道细胞因子和 T 细胞止血作用
  • 批准号:
    8357367
  • 财政年份:
    2011
  • 资助金额:
    $ 9.57万
  • 项目类别:

相似海外基金

Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.57万
  • 项目类别:
    Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
  • 批准号:
    2897580
  • 财政年份:
    2023
  • 资助金额:
    $ 9.57万
  • 项目类别:
    Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
  • 批准号:
    10658324
  • 财政年份:
    2023
  • 资助金额:
    $ 9.57万
  • 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
  • 批准号:
    10794761
  • 财政年份:
    2023
  • 资助金额:
    $ 9.57万
  • 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
  • 批准号:
    2304430
  • 财政年份:
    2023
  • 资助金额:
    $ 9.57万
  • 项目类别:
    Cooperative Agreement
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
  • 批准号:
    23K15543
  • 财政年份:
    2023
  • 资助金额:
    $ 9.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
  • 批准号:
    MR/X00466X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 9.57万
  • 项目类别:
    Fellowship
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
  • 批准号:
    10720234
  • 财政年份:
    2023
  • 资助金额:
    $ 9.57万
  • 项目类别:
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
  • 批准号:
    10976161
  • 财政年份:
    2023
  • 资助金额:
    $ 9.57万
  • 项目类别:
HIV Reservoir and Gene Modified Cell Dynamics Following Autologous Stem Cell Transplantation
自体干细胞移植后的 HIV 储库和基因修饰细胞动力学
  • 批准号:
    10700521
  • 财政年份:
    2023
  • 资助金额:
    $ 9.57万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了